Tag: Biologic disease-modifying anti-rheumatic drugs (bDMARDs

1. Treatment with biologics in pediatric patients with moderate to severe psoriasis was significantly associated with greater reduction in psoriasis severity than methotrexate, though methotrexate remains an effective treatment for the condition. Evidence Rating: 2 (Good) Psoriasis is a highly debilitating chronic inflammatory skin disorder that affects up to 1.37% of...
1. Ixekizumab, an IL-17 inhibitor, elicits disease response in patients with non-radiographic active axial spondyloarthritis who have failed treatment with NSAIDs. Evidence Rating Level: 1 (Excellent) Axial spondyloarthritis is a chronic inflammatory disease of the axial skeleton that is typically treated with non-steroidal anti-inflammatory drugs (NSAIDs). Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have...
1. Ixekizumab, an IL-17 inhibitor, elicits disease response in patients with non-radiographic active axial spondyloarthritis who have failed treatment with NSAIDs. Evidence Rating Level: 1 (Excellent) Axial spondyloarthritis is a chronic inflammatory disease of the axial skeleton that is typically treated with non-steroidal anti-inflammatory drugs (NSAIDs). Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have...